CAS: 25016-11-9; 1-Methyl-1H-Pyrazole-4-Carbaldehyde

相似化合物

63874-95-3 821767-61-7 112029-98-8

上下游产品

CAS号930-36-9 1-甲基吡唑 | CAS号68-12-2 N,N-二甲基甲酰胺 | CAS号18655-47-5 甲烷三甲醛 | CAS号60-34-4 甲基肼 | CAS号15803-02-8 4-溴-1-甲基-1H-吡唑 | CAS号10025-87-3 三氯氧磷 | CAS号5952-92-1 1-甲基吡唑-4-甲酸 | CAS号891494-63-6 6-溴-3-(1-甲基-1H-... | CAS号735241-98-2 4-(氯甲基)-1-甲基-1H-吡唑 | CAS号66121-71-9 1-甲基吡唑-4-甲腈 | CAS号112029-98-8 1-甲基-4-羟甲基吡唑 | CAS号754159-15-4 1-甲基-1H-吡唑-4-乙腈 | CAS号689251-97-6 (2E)-3-(1-甲基-1H... | CAS号43193-15-3 1H-Pyrazole-4-c...

1,4-二甲基吡唑置于iron(III) Sulfate,水体系中,用 乙腈 用作溶剂,化学反应 12.0H,以48%的收率获得1-甲基-1H-吡唑-4-甲醛
参考文献:高选择性和高转化率的苄基 C-H 键的铁离子浓度控制的有氧光氧化
标题:高选择性和高转化率的苄基 C-H 键的铁离子浓度控制的有氧光氧化
摘要:报道了 Fe(III) 促进的苄基 C-H 键的高度选择性光氧化,提供相关的羰基产物.通过改变铁盐的浓度,甲基芳烃可以在紫外线照射下被选择性氧化,分别提供芳香醛或酸.通过该协议,乙基芳烃的氧化提供了相应的苯乙酮.推断该反应涉及不同浓度催化剂的不同途径,用于醛和酸之间的替代选择性.可重复使用的催化剂,高转化率和选择性使这种氧化成为合成芳香羰基化合物的绿色经济方案.
Doi:10.1016/j.Tet.2021.132298

专利信息

专利号:US-2024309003-A1
优先权日:2021-05-04
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN; PANDYA BHAUMIK; KAPLAN ALAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-12319691-B2
优先权日:2020-05-04
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：CZABANIUK LARA C; HOPPER TIMOTHY; HOUZE JONATHAN B; RESCOURIO GWENAELLA; SANTORA VINCENT; WANG HAOXUAN; WHITE RYAN D; WONG ALICE R; WU YONGWEI
权利人:AMGEN INC; VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-12428425-B2
优先权日:2020-05-04
标 题:Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：CZABANIUK LARA C; HOPPER TIMOTHY; HOUZE JONATHAN B; PANTELEEV JANE; RESCOURIO GWENAELLA; SANTORA VINCENT; WANG HAOXUAN; WHITE RYAN D; WONG ALICE R; WU YONGWEI; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
权利人:AMGEN INC; VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:WO-2025125811-A1
优先权日:2023-12-12
标题:Heterocyclic compounds and their use for the treatment of neurological disorders
发明人：PLOWRIGHT ALLEYN THOMAS; PFEIFFER THOMAS; MÄRCHER-RØRSTED EMIL; DUCKWORTH EDWARD JOSEPH
权利人:ONTRACK THERAPEUTICS LTD
摘要:The present invention relates to novel synthetic compounds of Formula (I) and (II) related to naturally occurring flavonoids such as 7,8-dihydroxyflavone (7,8-DHF). The invention further relates to the method of synthesis, the use of these compounds as research tools and their use as pharmaceuticals.

专利号:WO-2008153870-A1
优先权日:2007-06-07
标题 :Synthesis of substituted-3-aminopyrazoles

专利号:US-7989438-B2
优先权日:2007-07-17
标题 :Therapeutic compounds
发明人：CONTE IMMACOLATA; HABERMANN JOERG; MACKAY ANGELA; NARJES FRANK; RICO FERREIRA MARIA DEL ROSARIO; STANSFIELD IAN
权利人:ANGELETTI P IST RICHERCHE BIO
摘要:A class of macrocyclic compounds of formula (I), wherein R 7 , A, Ar, B, D, F, M, Q 1 , Q 2 , W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.